Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study
DiscussionMelatonin has been found to positively impact our immune system, inhibit angiogenesis, stimulate apoptosis in malignant cells, and act as a potent antioxidant. Previous clinical trials have used similar doses of melatonin with positive results, particularly in advanced stages of cancer. Previous animal and human studies have found the toxicity of the hormone to be low. Considering the potential benefits and limited risks of melatonin, as well as its global availability, it may be a suitable candidate for an adjuvant treatment in patients with uveal melanoma.Trial registrationOur trial protocol has been approved a...
Source: Trials - March 26, 2023 Category: Research Source Type: clinical trials
Retrospective Register for Uveal Melanoma
Condition: Uveal Melanoma Intervention: Other: any therapy suitable Sponsor: Medical University of Vienna Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 17, 2023 Category: Research Source Type: clinical trials
